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Abstract
Background:  Transforming growth factor-beta (TGF-beta) is known to exert multiple regulatory
functions in the human placenta, including inhibition of estrodial production. We have previously reported
that TGF-beta1 decreased aromatase mRNA levels in human trophoblast cells. The objective of this study
was to investigate the molecular mechanisms underlying the regulatory effect of TGF-beta1 on aromatase
expression.
Methods: To determine if TGF-beta regulates aromatase gene transcription, several reporter constructs
containing different lengths of the placental specific promoter of the human aromatase gene were
generated. JEG-3 cells were transiently transfected with a promoter construct and treated with or without
TGF-beta1. The promoter activity was measured by luciferase assays. To examine the downstream
signaling molecule mediating the effect of TGF-beta on aromatase transcription, cells were transiently
transfected with dominant negative mutants of TGF-beta type II (TbetaRII) and type I receptor (ALK5)
receptors before TGF-beta treatment. Smad2 activation was assessed by measuring phophorylated Smad2
protein levels in cytosolic and nuclear fractions. Smad2 expression was silenced using a siRNA expression
construct. Finally, aromatase mRNA half-life was determined by treating cells with actinomycin D together
with TGF-beta1 and measuring aromatase mRNA levels at various time points after treatment.
Results and Discussion: TGF-beta1 inhibited the aromatase promoter activity in a time- and dose-
dependent manner. Deletion analysis suggests that the TGF-β1 response element resides between -422
and -117 nucleotides upstream from the transcription start site where a Smad binding element was found.
The inhibitory effect of TGF-beta1 was blocked by dominant negative mutants of TbetaRII and ALK5. TGF-
beta1 treatment induced Smad2 phosphorylation and translocation into the nucleus. On the other hand,
knockdown of Smad2 expression reversed the inhibitory effect of TGF-beta1 on aroamtase transcription.
Furthermore, TGF-beta1 accelerated the degradation of aromatase mRNA.
Conclusion: Our results demonstrate that TGF-beta1 exerts regulatory effects on aromatase gene at
both transcriptional and post-transcriptional levels. The transcriptional regulation of aromatase gene by
TGF-beta1 is mediated by the canonical TGF-beta pathway involving TbetaRII, ALK5 and Smad2. These
findings further support the role of TGF-beta1 in regulating human placental functions and pregnancy.
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Background
Transforming growth factor-β (TGF-β) regulates many
physiological processes, including reproduction [1-3].
During human pregnancy, TGF-β regulates placental tro-
phoblast cell proliferation and differentiation, as well as
hormone production [2,4-8]. TGF-β signaling is initiated
at the cell surface by interaction of the ligand with recep-
tor complexes that are composed of type I and type II
receptor serine/threonine protein kinases [9]. In general,
TGF-β interacts with its specific type II receptor (TβRII)
and a type I receptor referred to as activin receptor-like
kinase 5 (ALK5) [9-11]. ALK5 activates Smad2 and Smad3
through phosphorylation [9-11]. Following activation,
Smad2 and Smad3 form complexes with a common Smad
(Smad4) and enter the nucleus where they interact with
other transcription factors, coactivators and corepressors
to regulate gene transcription [12-14].
Aromatase, encoded by the CYP19 gene, is a key enzyme
involved in estrogen biosynthesis [15]. The CYP19 gene
has 9 coding exons (exon II-X) and the 5' untranslated
region is encoded by exon I which is alternatively used by
different tissues [15]. The gene uses multiple promoters in
a tissue-specific manner, resulting in a tissue-specific reg-
ulation of the aromatase activity [16]. Although aro-
matase transcripts in different tissues have their own
unique Exon I, they are spliced onto a common site
upstream of the translation initiation site in exon II, thus
resulting in the identical aromatase protein [17]. TGF-β
has been found to regulate human aromatase expression
in a tissue-specific manner. It decreased aromatase mRNA
levels and activity in trophoblast cells [18], fetal hepato-
cytes [19], adipose stromal cells [5,20] and skin fibroflasts
[21]. However, in osteoblast-like cells and THP-1 cells,
TGF-β1 has been found to stimulate aromatase gene tran-
scription [22]. In a leukaemic cell line FLG29.1, TGF-β1
stimulated aromatase expression and enzyme activity
[23].
We have previously reported that TGF-β1 decreased aro-
matase mRNA levels in trophoblast cells [5]. To determine
the mechanisms underlying this action, we examined the
5' flanking region of the placental specific exon I.1 of the
aromatase gene and identified several Smad binding ele-
ments. We therefore proposed that TGF-β acts through the
Smad pathway to inhibit aromatase transcription. Since a
decrease in mRNA level may also be resulted from a
decrease in mRNA stability, we also investigated whether
TGF-β1 regulates aromatase mRNA stability.
Methods
Cell culture
JEG-3 cells were purchased from American Type Culture
Collection (Rockville, MD). The cells were cultured in
minimal essential medium (MEM, Canadian Life Tech-
nologies, Inc.) containing 10% fetal bovine serum (FBS,
Sigma-Aldrich Canada Ltd, Oakville, ON) and antibiotics
(100 IU/m penicillin, and 100 μg/ml streptomycin, pur-
chased from Invitrogen Canada Inc. Burlington, ON).
Expression constructs
Expression constructs for constitutively active and domi-
nant negative ALK5, and dominant negative TβRII were
kindly provided by Dr. L. Attisano (Univ of Toronto).
Luciferase reporter constructs were generated using pGL3
basic luciferase reporter vector (Promega, Madison, WI).
To obtain DNA fragments containing different lengths of
the exon I.1 5' flanking sequence (+120 to -2538, +120 to
-1333, +120 to -714, +120 to -422, and +120 to -117),
PCR was performed using genomic DNA extracted from
JEG-3 cells as the template. All PCRs were carried out for
30 cycles using a common antisense primer, 5'-AGATTAA-
GAGATACATACGCG-3', and a specific sense primers (5'-
CCCGGTACCCCAGATGATCTTTCCCAGGAA-3' for
Arom -2538 construct; 5'-CTGTGGAACCATGAGC CA
ATT-3' for Arom-1333; 5'-GCATTGGAGATACGGAAG-
TAA-3' for Arom -714; 5'-TGTAGAA CAATG TG GT
GTGTG-3' for Arom-422; and 5'-AGACCTTGCTGAGATT-
AGATC-3' for Arom-117). The resulting DNA fragments
were first cloned into pCRII vector using a TOPO cloning
kit (Invitrogen). The inserts were then cut out from pCRII
vector using KpnI and XhoI (for Arom -1333, Arom -714
bp, Arom -422 bp and Arom -117 bp) and KpnI and NheI
(for Arom -2541) respectively, and then subcloned into
the pGL3-basic vector. All promoter constructs were fully
sequenced to verify their identities.
Transient transfection and luciferase assay
JEG-3 cells were seeded into 6-well plates at a density of 2
× 105  cells/well and incubated in MEM containing
10%FBS for 24 hours. Transient transfection was carried
out using a 25 kDa polyethylenimine (PEI, Sigma-
Aldrich) as previously described [24]. After transfection
for 4 h, the medium was replaced with MEM supplied
with 10% FBS and cells were allowed to be recovered for
different lengths of time. After treatment with TGF-β1,
cells were then lysed in 250 μl of lysis buffer (20 mM Tris
PH 7.4/0.1% TritonX-100). The supernatant was collected
for both luciferase and β-gal assays. To determine the luci-
ferase activity, 100 μl of luciferase substrate (Promega)
was added to 30 μl supernatant and the total light emis-
sion during the initial 10 seconds of the reaction was
measured using a luminometer. For β-gal assay, 30 μl of
supernatant was added into 270 μl of reaction mixture (1
ml contains 244 μl of 4 mg/ml of 2-Nitrophenyl-β-D-
Galactopyranoside (ONPG), 2.22 μl of 0.5 M MgSO4,
3.89 μl of β-mercaptoethanol, 186.2 μl of 0.4 M sodium
phosphate buffer, and 563.9 μl of water, and all chemicals
were purchased from Sigma-Aldrich), mixed well and
incubated at 37°C for 30 min or until a yellow colorReproductive Biology and Endocrinology 2009, 7:146 http://www.rbej.com/content/7/1/146
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change was detectable. The reaction was then terminated
by the addition of 500 μl of 1 M Na2CO3 and absorbance
at 410 nm was measured using a spectrophotomer. The
luciferase assay data were normalized by β-gal activity and
expressed as relative luciferase activity.
Treatment with TGF- 1
Cells were plated into 6-well plates at the density of 2 ×
105cells/well and allowed to grow overnight. To deter-
mine the effect of TGF-β1 on aromatase gene transcrip-
tion, cells were either treated with different
concentrations of TGF-β1 for 2 hours or 1 ng/ml of TGF-
β1 for different time periods (2 h, 6 h, 12 h and 24 h).
Silencing of Smad2 expression
Smad2 expression was knockdown using its siRNA. The
published Smad2 siRNA sequence (UCUUUGUGCA-
GAGCCCCAAtt [25]) was cloned into the pSuper vector
(Oligoengine, Seattle, WA), and JEG-3 cells were tran-
siently transfected with either the control pSuper vector or
the siRNA for Smad2 for 4 h. After recovering for 12, 24,
48 and 72 h, protein extract was prepared from cells and
Western blotting was performed using an antibody
against human Smad2 (Cell Signalling). To determine the
effect of Smad2 silencing on TGF-β action, cells were first
transfected with the control or siRNA plasmid for 4 h and
recovered for 24 h before being treated with TGF-β1 (1 ng/
ml) for 6 h.
Protein extraction and Western blot analysis
The whole cell extraction was carried out as described pre-
viously with some modification [26]. Briefly, JEG-3 cells
were plated using a density of 6 × 105 cells/dish in 60-mm
dishes and incubated overnight. Following treatment with
1 ng/ml TGF-β1 for 30 min, the cells were lysed in lysis
buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100,
0.5% deoxycholate, and 1% SDS) containing 1 mM dithi-
othreitol, 1 mM Na3VO4, 5 mM NaF, 100 mM EDTA, 10
mg/ml aprotinin, and 100 mM phenylmethysulfonyl flu-
oride. Nuclear proteins and cytoplasm proteins were
extracted using Nuclear Extraction Kit (Panomics) follow-
ing the manufacturer's protocols and stored at -20°C until
Western blot analysis. Proteins (40 μg) were separated by
SDS-polyacrylamide gel electrophoresis in 12% gels. The
proteins were transferred electrophoretically onto polyvi-
nylidene difluoride membranes (Immobilon-P, Millipore
Corp., Bedford, MA). After blocking with 5% milk in TBS-
T, the membranes were incubated with rabbit anti-human
phospho-Smad2 (1:1000 dilution, Cell Signaling) or
phosphor-Smad3 (1:1000 dilution, Cell Signaling), or
mouse anti-human actin (1:1000 dilution, Sigma) anti-
bodies at 4°C overnight. The membranes were subse-
quently probed with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse (1:5000 dilution, Amersham) at
room temperature for 1 h. Signals were detected using a
ECL-Plus kit (Amersham) according to the instructions of
the manufacturer.
Aromatase mRNA stability assays
To study the effect of TGF-β1 on aromatase mRNA stabil-
ity, JEG-3 cells were seeded at a density of 1 × 106 cells/60
mm dish. 24 h after plating, cells were treated with 2 μg/
ml actinomycin D (Sigma), either alone or in the presence
of 1 ng/ml of TGF-β1, in serum free medium. The cells
were then harvested at time 0 (pretreatment) and 6, 12,
24, 36 and 48 h after treatment with TGF-β1. Total RNA
was then extracted using Trizol reagent (Invitrogen) fol-
lowing the manufacturer's recommended protocol and
reversed transcribed into cDNA as previously described
[5]. Aromatase mRNA levels were determined using RT-
PCR. GAPDH was used as internal control to normalize
the aromatase mRNA level. The GAPDH sense primer was
5'-AAGGTCATCCCTGAGCTGAAC, and antisense primer
was 5'-CGCCTGCTTCACCACCTTCTA. Primers used in
aromatase PCR were sense: 5'-GCTGCAGTGCATCGG-
TATGCA-3', and antisense: 5'-ACTCGAGTCTGTGCATC-
CTTC-3'. Validation assays were performed to determine
the proper cycle number and the numbers chosen for aro-
matase (32 cycles) and GAPDH (22 cycles) are in the lin-
ear range of amplification.
Statistical analysis
All transfection assays were performed in triplicate and
repeated at least three times. The relative luciferase activity
shown in figures was the Mean ± SEM for triplicate wells
from one representative experiment. Statistical analysis
was done with one-way ANOOVA, followed by a Student-
Newman-Keul's multiple comparison tests using Graph
Pad InStat software (Graph Pad Inc., San Diego, CA). For
comparison between two groups, Student's t  test was
used. Differences were considered statistically significant
at P < 0.05.
Results
TGF-β1 inhibits aromatase gene transcription
Examination of the major promoter region that directs
placenta-specific expression of the aromatase gene reveals
the presence of four Smad binding elements (SBE) [27],
CAGAC, located at +93 to +97, -114 to -118, -118 to -122,
and -1186 to -1182 (Fig. 1A). This suggests that the TGF-β
family may regulate aromatase transcription via the Smad
pathway. Since TGF-β1 decreased aromatase mRNA [5],
we therefore tested its effect on aromatase gene transcrip-
tion. Five promoter constructs containing different
lengths of the 5' flanking sequence of the exon I.1, desig-
nated as Arom -2538, Arom -1333, Arom -714, Arom -
422, and Arom -117, were made and used to test the effect
of TGF-β1. JEG-3 cells were transiently transfected with a
luciferase construct and then treated with or without TGF-
β1. TGF-β1 inhibited promoter activities in Arom -2538,Reproductive Biology and Endocrinology 2009, 7:146 http://www.rbej.com/content/7/1/146
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Placental aromatase promoter constructs and the effect of TGF-β1 on promoter activities Figure 1
Placental aromatase promoter constructs and the effect of TGF-β1 on promoter activities. A) Various lengths (-
2538 to -117) of the 5' flanking region of the placental specific exon 1 were cloned into a luciferase reporter construct pGL3 
basic. Smad binding elements (SBE) are shown at the red box region. JEG-3 cells cultured in 6-well plates were transfected with 
these luciferase constructs (1 μg) and then treated with or without TGF-β1 (1 ng/ml) for 6 h. B) Cells were transfected with 
Arom -714 construct and then treated with TGF-β1 (1 ng/ml) for the duration as indicated. C) Cells were transfected with 
Arom -714 - and then treated with different concentrations of TGF-β1 for 6 h. In these experiments, a β-galactosidase expres-
sion vector (0.5 μg) was co-transfected into cells for normalizing transfection efficiency. Relative luciferase activity was calcu-
lated as the ratio of luciferase/β-gal. Data are mean ± SEM of three replicates from one experiment. The experiment has been 
repeated twice with similar results. *, P < 0.05 verse empty vector control.
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Arom -1333, Arom -714, and Arom -422 constructs. Dele-
tion between -422 and -117 abolished the basal promoter
activity as well as the inhibitory effect of TGF-β1 (Fig. 1A).
The dose-dependent and time-course effects of TGF-β1
were subsequently tested using promoter construct Arom
-714. A significant decrease in aromatase promoter activ-
ity was observed at 2 to 12 h after TGF-β1 treatment (Fig.
1B). At 6 h after treatment, all doses of TGF-β1 (0.1 to 10
ng/ml) significantly inhibited luciferase activity; with a
maximal effective dose observed at 1 ng/ml (Fig. 1C).
TGF-β1 acts through TβRII, ALK5, and Smad2 to regulate 
aromatase gene transcription
To confirm that TGF-β1 acts through its specific receptors
and the Smad pathway to regulate aromatase gene tran-
scription, several experiments were performed. First, cells
were transfected with dominant negative mutant of TβRII,
or its vector control (pCMV5) and then treated with or
without 1 ng/ml TGF-β1. As shown in Fig. 2A, TGF-β1
treatment decreased luciferase activity in the pCMV5-
transfected cells, but not in the dominant negative TβRII-
transfected cells, indicating that dominant negative TβRII
reversed the inhibitory effect of TGF-β1 on aromatase
gene transcription. Second, the involvement of ALK5 in
TGF-β1-regulated aromatase transcription was examined
using both constitutive active and dominant negative
mutants. Transfection of the constitutively active ALK5
inhibited the aromatase promoter activity to a similar
extend as TGF-β1 treatment (Fig. 2B). On the other hand,
overexpression of dominant negative ALK5 completely
blocked the effect of TGF-β1 on aromatase promoter activ-
ity (Fig. 2B).
We subsequently investigated if the Smad pathway is
involved in the TGF-β1-regulated aromatase transcription.
First, protein samples were extracted from cells at 30 min
after TGF-β1 treatment and immunoblotting was per-
formed. TGF-β1 strongly induced Smad2 phosphoryla-
tion (Fig. 3A). Consistent with our previous report that
Smad3 expression level is very low in JEG3 cells [28],
pSmad3 was only weakly detected in the TGF-β1-treated
cells (Fig. 3A). To further confirm the activation of Smad2,
protein samples were prepared from cytoplasmic and
nuclear fractions of the control and TGF-β1-treated cells.
Treatment with TGF-β1 resulted in strong accumulation of
phosphorylated Smad2 in the nucleus (Fig. 3B). To
directly examine the role of endogenous Smad2, we gen-
erated a siRNA construct to silence Smad2 expression.
Compared to the vector control, transfection with
siSmad2 construct resulted in a decrease in Smad2 protein
levels at 24, 48 and 72 h after transfection (Fig. 3C). When
cells were transfected with siSmad2 construct before TGF-
β1 treatment, we found that knockdown of Smad2 com-
pletely reversed the effect of TGF-β1 on aromatase tran-
scription (Fig. 3D).
TGF-β1 decreased aromatase mRNA stability
Since the decrease in aromatase mRNA levels could also
be due to a decrease in its stability, we tested if TGF-β1 reg-
ulated aromatase mRNA degradation. Cells were treated
with a transcription inhibitor actinomycin D and the
decay of aromatase mRNA was measured from 6 to 48 h.
At all time points tested, aromatase mRNA levels were sig-
TGF-β1 acts through TβRII and ALK5 to inhibit aromatase  transcription Figure 2
TGF-β1 acts through TβRII and ALK5 to inhibit aro-
matase transcription. A) Cells were transfected with 
Arom -714 construct, the control vector pCMV5 or domi-
nant negative TβRII. At 24 h after transfection, they were 
treated with the control medium or TGF-β1 (1 ng/ml). B) 
Cells were transfected with Arom -714 construct, control 
vector pCMV5, the dominant negative ALK5 (ALK5-kd) and 
the constitutively active ALK5 (ALK5-ca). A β-galactosidase 
expression vector (0.5 μg) was simultaneously co-transfected 
into cells for normalizing transfection efficiency.
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Smad2 is involved in TGF-β1-inhibited aromatase transcription Figure 3
Smad2 is involved in TGF-β1-inhibited aromatase transcription. A) TGF-β1 induced Smad2 phosphorylation. Cells 
were treated with TGF-β1 (1 ng/ml) for 1 h and Smad2 and Smad3 phosphorylation was determined by Western blot analysis 
using specific antibodies. β-actin was used for the loading control. B) TGF-β1 induced Smad2 nuclear translocation. Cells were 
treated with TGF-β1 as above and cytoplamic and nuclear proteins were analyzed for the phosphorylated Smad2 levels. C) Val-
idation of Smad2 siRNA. Cells were transfected with 2 μg of pSuper empty vector or Smad2 siRNA (siSmad2) cloned in pSu-
per. At various time points after transfection, cell lysates were prepared and probed for Smad2. D) Smad2 siRNA reversed the 
TGF-β1-inhibited aromatase transcription. Cells were transfected with pSuper or pSuper carrying Smad2 siRNA. Smad2 siRNA 
blocked the effect of TGF-β1 on aromatase transcription. Knockdown of Smad2 by its siRNA was confirmed by Western blot-
ting.
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TGF-β1 decreased aromatase mRNA stability Figure 4
TGF-β1 decreased aromatase mRNA stability. Cells seated in 24-well plates were treated with 2 μg/ml actinomycin D 
alone or in combination with TGF-β1 (1 ng/ml). Cells were harvested at time 0 (pretreatment), 6, 12, 24, 36 and 48 h after 
treatment with TGF-β1. Aromatase mRNA levels were determined by semi-quantitative PCR. A) Representative results from 
one experiment. B) The half-life (T1/2) of aromatase transcript is defined as the time required for aromatse mRNA levels to 
drop to 50% of its starting values (0 time point). In this study, the T1/2 value of aromatse mRNA was reduced from 36 h in the 
control to 20 h in the treatment groups with TGF-β1. Data are mean ± SEM of three experiments. *, P < 0.05 verse the time 
matched control.
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nificantly lower in TGF-β1-treated cells than in the control
cells (Fig. 4). The half-life of aromatase transcript was
approximately 36 h and 20 h, respectively, in the control
and TGF-β1-treated cells (Fig. 4B), suggesting that TGF-β1
decreased the half-life of aromatase mRNA by 16 h.
Discussion
Aromatase plays important roles during pregnancy as it is
the key enzyme involved in estrogen production. TGF-β
has been reported to regulate placental development and
functions, including estrogen synthesis. In this study, we
demonstrated that TGF-β1 inhibits aromatase transcrip-
tion and decreases aromatase mRNA stability, thus pro-
viding new insights into the molecular mechanisms
underlying the effect of TGF-β1 in placental steroidogene-
sis.
Using luciferase reporter assays, we found that TGF-β1
inhibited promoter activity of aromatase gene. Deletion
analysis showed that removal of nucleotides between -
422 to -117 resulted in a loss of response to TGF-β1, as
well as the basal promoter activity. This finding suggests
that the TGF-β response element resides in the region
between -117 and -422. Since there are two overlapping
SBEs located at -114 to -118 and -118 to -122, it is possi-
ble that these SBEs are important in mediating the effect
of TGF-β1 on aromatase transcription. Additional SBEs
found in +93 to +97 and -1186 to -1182 may not partici-
pate in TGF-β-regulated aromatase transcription. Our
Proposed model of TGF-β action in estrogen production in trophoblast cells Figure 5
Proposed model of TGF-β action in estrogen production in trophoblast cells. TGF-β binds to its serine/threonine 
receptor complex (TβRII and ALK5) to activate Smad2. The phosphorylated Smad2 forms a complex with Smad4 and translo-
cate to the nucleus, where the complex could interact with other transcription factors (TF) and co-repressors to inhibit aro-
matase gene transcription. TGF-β also decreases aromatase mRNA stability, which contributes to a decrease in aromatase 
mRNA levels. The decrease in aromatase mRNA may lead to a decrease in aromatase activity and thus estrogen biosynthesis in 
trophoblast cells.
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finding that -117 to -422 region is important for main-
taining the basal promoter activity is consistent with pre-
vious studies which showed that constructs containing up
to -125 bp of the placenta aromatase promoter had no
transcriptional activity [29,30].
TGF-β signals through a receptor complex containing type
I and type II serine/threonine kinases. It binds to type II
receptors which in turn recruit and phosphorylate type I
receptors, resulting the activation of type I receptors. Sev-
eral type I receptors have been reported to mediate TGF-β
signaling, including ALK1 and ALK5 [11]. While ALK5 is
expressed in a variety of cells, ALK1 expression is restricted
to endothelial cells [11]. In this study, we found that the
dominant negative mutant of TβRII and ALK5 completely
reversed the inhibitory effect of TGF-β1 on aromatase
transcription while constitutively ALK5 mimicked the
effect of TGF-β1. These results indicate that TGF-β1 acts
through TβRII and ALK5 to regulate aromatase expression.
ALK5 is known to activate the Smad2/3 pathway [9,11].
Consistent with this, we found that TGF-β1 induced
Smad2 phosphorylation and nuclear accumulation in
JEG3 cells. Silencing of Smad2 expression using siRNA
resulted in the loss of TGF-β1 inhibitory effect on aro-
matase transcription, demonstrating that Smad2 mediates
the effect of TGF-β1 on these cells. TGF-β1 also activated
Smad3; however, since Smad3 expression is very low in
JEG3 cells, it is unlikely that it plays a role in TGF-β1-reg-
ulated aromatase promoter activity.
In addition to regulating aromatase transcription, TGF-β1
also decreased aromatase mRNA stability since we found
that in the presence of actinomycin D, TGF-β1 was able to
reduce aromatase mRNA levels by shortening its half-life.
The mechanism whereby TGF-β1 reduces aromatase
mRNA stability is unclear at present. Recently, it was
reported that the tissue specific alternative exon I of the
aromatase gene play an important role in the posttran-
scriptional regulation of aromatase gene expression [31].
Whether or not the TGF-β1 pathway can target the placen-
tal specific exon I.1 to regulate aromatase mRNA stability
remains to be determined.
Conclusion
In summary, we have shown that TGF-β1 exerts its regula-
tory effects on aroamtase mRNA expression at both tran-
scriptional and post-transcriptional levels. TGF-β1 acts
through the canonical TGF-β signaling pathway involving
TβRII, ALK5, and Smad2 to inhibit aromatase transcrip-
tion and through unknown mechanisms to decrease
aroamtase mRNA stability. This could in turn decrease
aromatase activity, leading to inhibition of estrogen bio-
synthesis (Fig. 5). These findings further support the role
of TGF-β1 in regulating human placental functions and
pregnancy.
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